Ionis Pharmaceuticals, Inc. beat EPS estimates 75% of the time across 16 reported quarters (12 beats, 4 misses), averaging +25.6% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-1.09 | $-0.70 | +35.8% | Beat | Q2 FY26 call |
| Q1 FY26 | $-0.89 | $-0.56 | +37.1% | Beat | |
| Q4 FY25 | $-1.31 | $-1.41 | -7.6% | Miss | Q4 FY25 call |
| Q3 FY25 | $-1.23 | $-0.80 | +35.0% | Beat | |
| Q2 FY25 | not reported | $0.70 | not reported | not reported | |
| Q1 FY25 | $-1.16 | $-0.93 | +19.8% | Beat | |
| Q4 FY24 | $-1.12 | $-0.66 | +41.1% | Beat | |
| Q3 FY24 | $-1.16 | $-0.95 | +18.1% | Beat | |
| Q2 FY24 | $-0.95 | $-0.45 | +52.6% | Beat | |
| Q1 FY24 | $-1.10 | $-0.98 | +10.9% | Beat | |
| Q4 FY23 | not reported | $-0.06 | not reported | not reported | |
| Q3 FY23 | $-1.01 | $-1.03 | -2.0% | Miss |
Back to IONS overview · IONS holders · IONS KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.